Literature DB >> 8378080

Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours.

H Kovar1, A Auinger, G Jug, D Aryee, A Zoubek, M Salzer-Kuntschik, H Gadner.   

Abstract

The p53 and MDM2 genes are part of a physiological pathway frequently impaired in human cancer. With the exception of tumours occasionally associated with hereditary predisposition, childhood malignancies have not been studied in detail yet. This is the first report on the analysis of p53 and MDM2 in a group of non-hereditary paediatric neoplasms referred to as the Ewing tumours (ETs). Thirty-seven primary tumours and cell lines from 19 patients were screened for the presence of p53 mutations. Only 5% of the primary tumour specimens were found to carry an alteration within this gene. However, p53 mutations were 10-fold enriched in ET cell lines, thus indicating a selective growth advantage in vitro. Strikingly, five out of nine alterations detected were missense mutations within codon 273, which were previously reported to impair only partially the normal p53 function. Two single-base substitutions occurred at codons 277 and 176, and two alterations were loss-of-function mutations. Investigation of the MDM2 gene revealed neither gene amplification in the primary tumours and cell lines nor significant overexpression in any of the cell lines. Our data therefore suggest that impairment of cellular mechanisms involving p53 is rare in a distinct group of childhood malignancies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378080

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Authors:  E de Alava; A Panizo; C R Antonescu; A G Huvos; F J Pardo-Mindán; F G Barr; M Ladanyi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Expression of mdm-2 and p53 protein in transitional cell carcinoma.

Authors:  M Barbareschi; S Girlando; G Fellin; U Graffer; L Luciani; P Dalla Palma
Journal:  Urol Res       Date:  1995

4.  p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.

Authors:  R Schneider-Stock; K Radig; Y Oda; W Mellin; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event.

Authors:  D C Mangham; A Cannon; X Q Li; S Komiya; M C Gebhardt; D S Springfield; A E Rosenberg; H J Mankin
Journal:  Clin Mol Pathol       Date:  1995-04

6.  Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types.

Authors:  P Thorner; J Squire; S Chilton-MacNeil; P Marrano; J Bayani; D Malkin; M Greenberg; A Lorenzana; M Zielenska
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

8.  BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression.

Authors:  Dorothea Douglas; Jessie Hao-Ru Hsu; Long Hung; Aaron Cooper; Diana Abdueva; John van Doorninck; Grace Peng; Hiro Shimada; Timothy J Triche; Elizabeth R Lawlor
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.

Authors:  J Keleti; M M Quezado; M M Abaza; M Raffeld; M Tsokos
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

10.  A molecular function map of Ewing's sarcoma.

Authors:  Maximilian Kauer; Jozef Ban; Reinhard Kofler; Bob Walker; Sean Davis; Paul Meltzer; Heinrich Kovar
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.